Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Analysts surveyed by LSEG are expecting Amazon to report revenue of $187 billion for its latest quarter on Thursday.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

President Donald Trump signed an executive order pulling the U.S. out of the W.H.O. Winter health woes from the dangerous cold snap, and a Tennessee hospital breaks a heart transplant record. Bradley ...

Retatrutide, Eli Lilly's drug candidate under development, showed around a 20% placebo-corrected weight loss at a similar stage in its trial but was tested in heavier patients. Novo Nordisk's ...

Retatrutide, Eli Lilly's drug candidate under development, showed around a 20% placebo-corrected weight loss at a similar stage in its trial but was tested in heavier patients. Novo Nordisk's ...

Not to be outdone, Lilly is also working on a new “next-generation weight-loss drug” retatrutide, which targets three hormones: GLP-1, GIPR and glucagon. However, analysts have said that premilinary ...

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in ...

JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...